# A Study in Patients With Advanced Cancers

Source: https://onco.cc/trials/nct05320588/  
OnCo record `nct05320588` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of BIO-106, Pembrolizumab in metastatic cancer, run by BiOneCure Therapeutics Inc., now recruiting.

## Summary

A Study in Patients With Advanced Cancers is a phase 1/2 interventional study registered as NCT05320588 by BiOneCure Therapeutics Inc., with 332 participants planned, started 2022-03-25 and due to reach its primary completion in 2024-04. Interventions recorded: BIO-106, Pembrolizumab. Conditions listed: Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05320588
- Phase: 1/2
- Setting: A Phase 1/2 Study of BIO-106 As Monotherapy or In Combination With Pembrolizumab in Patients With Advanced Cancers (StarBridge-1)
- Sponsor: BiOneCure Therapeutics Inc.
- Enrolled: 332

## Sources

- ClinicalTrials.gov NCT05320588: https://clinicaltrials.gov/study/NCT05320588

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [BIO-106](https://onco.cc/drugs/bio-106/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)

---
JSON: https://onco.cc/api/v1/entities/nct05320588.json